66 related articles for article (PubMed ID: 10470226)
1. Thyroid peroxidase (TPO) as a tumor marker in the follow-up of differentiated thyroid carcinomas with surgical and ablative radioiodine therapy. An assessment after evaluation.
Franke WG; Zöphel K; Wunderlich G; Kühne A; Schimming C; Kropp J; Bredow J
Anticancer Res; 1999; 19(4A):2711-6. PubMed ID: 10470226
[TBL] [Abstract][Full Text] [Related]
2. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
[TBL] [Abstract][Full Text] [Related]
3. Can thyroid peroxidase be used as a complementary tumor marker besides thyroglobulin? Preliminary experience with determination of TPO in differentiated thyroid carcinomas.
Franke WG; Schimming C; Wunderlich G
Anticancer Res; 1997; 17(4B):2999-3002. PubMed ID: 9329585
[TBL] [Abstract][Full Text] [Related]
4. [Methodical evaluation of immunoluminometric determination of thyroid peroxidase in serum].
Herbig J; Lange D; Elser H; Georgi P
Nuklearmedizin; 1996 Jun; 35(3):94-8. PubMed ID: 8710531
[TBL] [Abstract][Full Text] [Related]
5. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
6. Thyroglobulin levels to follow-up patients with treated differentiated thyroid carcinoma.
Moser E; Braun S; Büell U; Kirsch CM; Tosch U; Wendt T
Cancer Detect Prev; 1984; 7(2):79-86. PubMed ID: 6424939
[TBL] [Abstract][Full Text] [Related]
7. Sequential changes in serum thyroid peroxidase following radioiodine therapy of patients with differentiated thyroid carcinoma.
Ozata M; Bayhan H; Bingöl N; Dündar S; Beyhan Z; Corakci A; Gundogan MA
J Clin Endocrinol Metab; 1995 Dec; 80(12):3634-8. PubMed ID: 8530612
[TBL] [Abstract][Full Text] [Related]
8. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.
Heemstra KA; Liu YY; Stokkel M; Kievit J; Corssmit E; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2007 Jan; 66(1):58-64. PubMed ID: 17201802
[TBL] [Abstract][Full Text] [Related]
9. Possible reasons for different pattern disappearance of thyroglobulin and thyroid peroxidase autoantibodies in patients with differentiated thyroid carcinoma following total thyroidectomy and iodine-131 ablation.
Thomas D; Liakos V; Vassiliou E; Hatzimarkou F; Tsatsoulis A; Kaldrimides P
J Endocrinol Invest; 2007 Mar; 30(3):173-80. PubMed ID: 17505148
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
11. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation].
Vincze B; Sinkovics I; Keresztes S; Gergye M; Boér A; Remenár E; Péter I; Szentirmay Z; Kremmer T; Kásler M
Magy Onkol; 2004; 48(1):27-34. PubMed ID: 15105893
[TBL] [Abstract][Full Text] [Related]
13. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
14. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
[TBL] [Abstract][Full Text] [Related]
15. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis.
Eustatia-Rutten CF; Smit JW; Romijn JA; van der Kleij-Corssmit EP; Pereira AM; Stokkel MP; Kievit J
Clin Endocrinol (Oxf); 2004 Jul; 61(1):61-74. PubMed ID: 15212646
[TBL] [Abstract][Full Text] [Related]
17. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
18. The quantitative measurement of autoantibodies to thyroglobulin and thyroid peroxidase by automated microparticle based immunoassays in Hashimoto's disease, Graves' disease and a follow-up study on postpartum thyroid disease.
Gilmour J; Brownlee Y; Foster P; Geekie C; Kelly P; Robertson S; Wade E; Braun HB; Staub U; Michel G; Lazarus JH; Parkes AB
Clin Lab; 2000; 46(1-2):57-61. PubMed ID: 10745983
[TBL] [Abstract][Full Text] [Related]
19. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
20. High-sensitive 2nd generation thyroglobulin immunoradiometric assay. Clinical application in differentiated thyroid cancer management.
Giovanella L; Ceriani L; Garancini S
Q J Nucl Med; 2002 Dec; 46(4):319-22. PubMed ID: 12411872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
